Reconstitution and Administration Instructions for Healthcare Professionals.
|
|
- Griselda Reed
- 5 years ago
- Views:
Transcription
1 Reconstitution and Administration Instructions for Healthcare Professionals.
2 Indication CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). Contraindications CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product. Important Safety Information Severe hypersensitivity reactions may occur. Because hypersensitivity reactions and HAE attacks may have similar symptoms, distinguishing between the two is important. Epinephrine should be immediately available to treat any acute severe hypersensitivity reaction and CINRYZE should be discontinued. Thrombotic events have been reported in patients receiving CINRYZE for routine prophylaxis and in patients receiving C1 esterase inhibitor products when used off-label at high doses. Monitor patients with known risk factors for thrombotic events. CINRYZE is made from human plasma. Products made from human plasma may contain infectious agents (e.g., viruses and, theoretically, the Creutzfeldt- Jakob Disease agent). The risk that such products will transmit an infectious agent has been reduced by screening donors, testing for the presence of infections, and by inactivating or removing a broad range of viruses during the manufacturing process. In the clinical trial, the most common adverse reactions observed by 5% of the 24 evaluable subjects after receiving CINRYZE were upper respiratory tract infection, sinusitis, rash, and headache. Before prescribing CINRYZE, please read the enclosed Full Prescribing Information. 2
3 Instructions for use. The following procedures are provided as general guidelines for the reconstitution and administration of CINRYZE. Use either the Mix2Vial transfer device or a commercially available double-ended needle. CINRYZE IS A LYOPHILIZED POWDER THAT IS SUPPLIED IN A VACUUM- SEALED VIAL. Always work on a clean surface and wash your hands before performing the following steps. Reconstitution, product administration, and handling of the administration set and needles must be done with caution. Percutaneous puncture with a needle contaminated with blood can transmit infectious viruses including HIV (AIDS) and hepatitis. Obtain immediate medical attention if injury occurs. Place needles in a sharps container after single use. Discard all equipment, including any reconstituted CINRYZE, in an appropriate container. Preparation and handling. Prior to reconstitution, CINRYZE should be protected from light. CINRYZE should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit. The reconstituted solution should be colorless to slightly blue and free from visible particles. Do not use if turbid or discolored. The vial of CINRYZE is for single use only. CINRYZE contains no preservative. Any vial that has been entered should be used promptly. Partially used vials should be discarded in accordance with biohazard procedures. Do not: mix CINRYZE with other materials. use if frozen. use after the expiration date. 3
4 Supplies needed. 2 Vials of CINRYZE (500 Units each) 2 Vials of Sterile Water for Injection, USP (diluent, 5 ml each) 2 Mix2Vial Transfer Devices Alcohol Prep Pads (wipes) Reconstitution. Two vials of reconstituted CINRYZE are combined for a single dose. Sterile Water for Injection, USP, is required and is not supplied with CINRYZE. Aseptic technique should be used during the reconstitution procedure. Bring the CINRYZE (powder) and Sterile Water for Injection, USP (diluent), to room temperature if previously refrigerated. 4
5 1. Remove the cap from the CINRYZE and diluent vials. 2. Cleanse the stoppers with an alcohol wipe or swab and allow them to dry prior to use. 5
6 3. Remove the protective covering from the top of the Mix2Vial transfer device package. Do not remove the device from the package. 4. Note: Vial of diluent must be accessed prior to vial of CINRYZE to prevent loss of vacuum. Place the diluent on a flat surface and insert the blue end of the device into the diluent vial, pushing down until the spike penetrates through the center of the stopper and the device snaps in place. The Mix2Vial transfer device must be positioned completely vertical prior to penetrating the stopper closure. 6
7 5. Remove the plastic package and discard it. Take care not to touch the exposed end of the device. 6. Place the vial of CINRYZE on a flat surface. Invert the diluent vial containing 5 ml Sterile Water for Injection, USP, and insert the clear end into the vial of CINRYZE, pushing down until the spike penetrates the rubber stopper and the device snaps in place. The Mix2Vial transfer device must be positioned completely vertical prior to penetrating the stopper closure. The Sterile Water for Injection, USP, will automatically flow into the vial of CINRYZE because the vacuum in the vial will draw in the diluent. If there is no vacuum in the vial, do not use the product. 7
8 7. Gently swirl (do not shake) the vial of CINRYZE until all powder is dissolved. Be sure that CINRYZE is completely dissolved. 8. Disconnect the vial of Sterile Water for Injection, USP, by turning it counterclockwise. Do not remove the clear end of the Mix2Vial transfer device from the vial of CINRYZE. One vial of reconstituted CINRYZE contains 5 ml of C1 esterase inhibitor at a concentration of 100 Units/mL. Reconstitute two vials of CINRYZE for one dose. Repeat steps 1 8 using a new Mix2Vial transfer device to reconstitute the second of two vials of CINRYZE. Do not reuse the Mix2Vial transfer device. 8
9 Administration. Use aseptic technique. After reconstitution, the solutions are colorless to slightly blue and clear. Do not use the product if the solutions are turbid or discolored. CINRYZE must be administered at room temperature within 3 hours after reconstitution. Supplies needed mL Syringe 2 Vials of Reconstituted CINRYZE Infusion Set With Winged Adapter (butterfly needle with tubing) Tourniquet Alcohol Prep Pads (wipes) Sharps Container Medical Tape Bandages Watch 9
10 1. Utilizing a sterile, disposable 10-mL syringe, draw back the plunger to admit 5 ml of air into the syringe. 2. Attach the syringe onto the top of the clear end of the Mix2Vial transfer device by turning it clockwise. 3. Invert the vial and inject air into the solution and then slowly withdraw the reconstituted CINRYZE into the syringe. 10
11 4. Detach the syringe from the vial by turning it counterclockwise and releasing it from the clear end of the Mix2Vial transfer device. 5. Using the same syringe, repeat steps 1 4 with a second vial of CINRYZE to make the complete dose. 6. Attach a suitable needle or infusion set with winged adapter, and inject intravenously. As a guideline, administer 1000 Units (reconstituted in 10 ml) of CINRYZE by intravenous injection at a rate of 1 ml per minute over 10 minutes. 7. Dispose of all unused solution, the empty vials, and the used needles and syringes in an appropriate container for throwing away waste that might hurt others if not handled properly. 11
12 Before prescribing CINRYZE, please read the enclosed Full Prescribing Information ViroPharma Incorporated. All rights reserved. CINRYZE, the CINRYZE logo and CINRYZESolutions are either trademarks or registered trademarks of ViroPharma Biologics, Inc. VIROPHARMA and the ViroPharma logo are trademarks of ViroPharma Incorporated. Mix2Vial is a registered trademark of Medimop Medical Projects, Ltd. in the United States and other jurisdictions. DD /2011
13 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CINRYZE safely and effectively. See full prescribing information for CINRYZE. CINRYZE (C1 Esterase Inhibitor [Human]) For Intravenous Use, Freeze-Dried Powder for Reconstitution Initial U.S. Approval: 2008 RECENT MAJOR CHANGES Warnings and Precautions, Thrombotic Events (5.2) Adverse Reactions, Postmarketing Experience (6.2) 11/ /2010 INDICATIONS AND USAGE CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE). DOSAGE AND ADMINISTRATION Intravenous Use Only Prior to reconstitution, protect from light. Store at 2 C - 25 C (36 F - 77 F). Do not freeze. FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Routine Prophylaxis against HAE attacks 2.2 Instructions for use 2.3 Preparation and Handling 2.4 Administration 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Hypersensitivity Reactions 5.2 Thrombotic Events 5.3 Transmissible Infectious Agents To obtain the required dose, reconstitute two CINRYZE vials with two vials Sterile Water for Injection, USP (5 ml each) using aseptic sterile technique. Administer at room temperature within 3 hours of reconstitution. Routine Prophylaxis Dosing Indication Dose Initial Infusion rate Routine prophylaxis against HAE attacks 1,000 Units Intravenous every 3 or 4 days 1 ml/min (10 min) DOSAGE FORMS AND STRENGTHS Approximately 500 Units (lyophilized) in an 8 ml vial. Maintenance infusion rate (if tolerated) 1 ml/min (10 min) CONTRAINDICATIONS Patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product (4). WARNINGS/PRECAUTIONS Hypersensitivity reactions may occur. Have epinephrine immediately available for treatment of acute severe hypersensitivity reaction (5.1). Thrombotic events have been reported in patients receiving CINRYZE for routine 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 10 OVERDOSAGE 11 DESCRIPTION prophylaxis. Thrombotic events also have been reported in patients receiving off-label high dose C1 esterase inhibitor therapy (5.2). Monitor closely patients with known risk factors for thrombotic events. CINRYZE is made from human plasma and may contain infectious agents e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent. (5.3) ADVERSE REACTIONS The most common adverse reactions observed were headache, nausea, rash, and vomiting. (5.1, 6.1) To report SUSPECTED ADVERSE REACTIONS, contact ViroPharma Biologics, Inc. at (877) or FDA at FDA-1088 or USE IN SPECIFIC POPULATIONS Pregnancy: No human or animal data. Use only if clearly needed. (8.1) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: January CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed FULL PRESCRIBING INFORMATION CINRYZE (C1 Esterase Inhibitor [Human]) Freeze-Dried Powder for Reconstitution 1 INDICATIONS AND USAGE CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE). 2 DOSAGE AND ADMINISTRATION For Intravenous Use, Freeze-Dried Powder for Reconstitution. 2.1 Routine prophylaxis against HAE Attacks A dose of 1,000 Units CINRYZE can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. CINRYZE is administered at an injection rate of 1 ml per minute. Table 1 Routine Prophylaxis Dosing Indication Dose Initial Infusion rate Maintenance infusion rate (if tolerated) 1 ml/min (10 min) Routine prophylaxis 1,000 Units Intravenous 1 ml/min against HAE attacks every 3 or 4 days (10 min) 2.2 Instructions for Use The procedures below are provided as general guidelines for the reconstitution and administration of CINRYZE. Use either the Mix2Vial transfer device or a commercially available double-ended needle. Always work on a clean surface and wash your hands before performing the following procedures. Reconstitution, product administration, and handling of the administration set and needles must be done with caution. Percutaneous puncture with a needle contaminated with blood can transmit infectious viruses including HIV (AIDS) and hepatitis. Obtain immediate medical attention if injury occurs. Place needles in a sharps container after single use. Discard all equipment, including any reconstituted CINRYZE in an appropriate container. 2.3 Preparation and Handling Prior to reconstitution, CINRYZE should be protected from light. CINRYZE should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted solution should be colorless to slightly blue, and free from visible particles. Do not use if turbid or discolored. Each vial of CINRYZE is for single use only. CINRYZE contains no preservative. Any vial that has been entered should be used promptly. Partially used vials should be discarded in accordance with biohazard procedures. Do not mix CINRYZE with other materials. Do not use if frozen. Do not use after expiration date. Reconstitution: Two vials of reconstituted CINRYZE are combined for a single dose. Sterile Water for Injection, USP, is required and not supplied with CINRYZE. 1. Aseptic technique should be used during the reconstitution procedure. 2. Bring the CINRYZE (powder) and Sterile Water for Injection, USP (diluent) (not supplied) to room temperature if refrigerated. 3. Remove caps from the CINRYZE and diluent vials. 4. Cleanse stoppers with an alcohol wipe or swab, and allow them to dry prior to use. 5. Remove protective covering from the top of the Mix2Vial transfer device package. Do not remove the device from the package. 6. Note: Diluent vial must be accessed prior to the vial of CINRYZE to prevent loss of vacuum. Place diluent on a flat surface and insert the blue end of the device into the diluent vial, pushing down until the spike penetrates through the center of the diluent vial stopper and the device snaps in place (Figure 1). The Mix2Vial transfer device must be positioned completely vertical prior to penetrating the stopper closure. 7. Remove the plastic package and discard it (Figure 2). Take care not to touch the exposed end of the device. 8. Place vial of CINRYZE on a flat surface. Invert diluent vial containing 5 ml Sterile Water for Injection, USP, and insert the clear end into the CINRYZE vial, pushing down until the spike penetrates the rubber stopper and the device snaps into place. The Mix2Vial transfer device must be positioned completely vertical prior to penetrating the stopper closure. The Sterile Water for Injection, USP will automatically flow into the vial of CINRYZE (Figure 3), because the vacuum in the vial will draw in the diluent. If there is no vacuum in the vial, do not use the product. 9. Gently swirl (do not shake) the CINRYZE vial until all powder is dissolved. Be sure that CINRYZE is completely dissolved (Figure 4). Disconnect the Sterile Water for Injection, USP vial by turning it counterclockwise (Figure 5). Do not remove the clear end of the Mix2Vial transfer device from the vial of CINRYZE. One vial of reconstituted CINRYZE contains 5 ml of C1 esterase inhibitor at a concentration of 100 Units/mL. Reconstitute two vials of CINRYZE for one dose. Repeat steps 1 to 9 above using an additional package containing a Mix2Vial transfer device to reconstitute the second of two vials of CINRYZE. Do not reuse the Mix2Vial transfer device. Figure 1 Figure 2 Figure 3 Figure 4 Figure Administration Two vials of reconstituted CINRYZE are combined for a single dose. 1. Use Aseptic Technique. 2. After reconstitution, the solutions are colorless to slightly blue and clear. Do not use the product if the solutions are turbid or discolored. 3. CINRYZE must be administered at room temperature within 3 hours after reconstitution. 4. Please refer to the illustrations in steps 7 to 9 included within the Patient Information Leaflet. Utilizing a sterile, disposable 10 ml syringe, draw back the plunger to admit 5 ml air into the syringe. 5. Attach the syringe onto the top of the clear end of the Mix2Vial transfer device by turning it clockwise. 6. Invert the vial and inject air into the solution and then slowly withdraw the reconstituted CINRYZE into the syringe. 7. Detach the syringe from the vial by turning it counterclockwise and releasing it from the clear end of the Mix2Vial transfer device. 8. Using the same syringe, repeat steps 4 to 7 with a second vial of CINRYZE to make the complete dose. 9. Attach a suitable needle or infusion set with winged adapter, and inject intravenously. As a guideline, administer 1,000 Units (reconstituted in 10 ml) of CINRYZE by intravenous injection at a rate of 1 ml per minute over 10 minutes. (See Clinical Studies, [14]) Please refer to the illustration in step 3 of the self administration section within the Patient Information Leaflet. 10. Dispose of all unused solution, the empty vial(s), and the used needles and syringes in an appropriate container for throwing away waste that might hurt others if not handled properly. 3 DOSAGE FORMS AND STRENGTHS CINRYZE is a lyophilized preparation available in a single-use vial that contains 500 Units (U) human C1 esterase inhibitor. Each vial must be reconstituted with 5 ml Sterile Water for Injection, USP (diluent) (not supplied). Two reconstituted vials must be used to make a single, 1,000 Units, dose. 4 CONTRAINDICATIONS CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product. 5 WARNINGS AND PRECAUTIONS 5.1 Hypersensitivity Reactions Severe hypersensitivity reactions may occur. The signs and symptoms of hypersensitivity reactions may include the appearance of hives, urticaria, tightness of the chest, wheezing, hypotension and/or anaphylaxis experienced during or after injection of CINRYZE. Consider treatment methods carefully, because hypersensitivity reactions may have symptoms similar to HAE attacks. In case of hypersensitivity, discontinue CINRYZE infusion and institute appropriate treatment. Have epinephrine immediately available for treatment of acute severe hypersensitivity reaction. (See Patient Counseling Information [17]) 5.2 Thrombotic Events Thrombotic events have been reported following administration of C1 esterase inhibitor products when used off-label at high doses. 2 Animal studies have supported a concern about the risk of thrombosis from intravenous administration of C1 esterase inhibitor products. 3 (See Sections 10 OVERDOSAGE and 13.2 Animal Toxicology and/or Pharmacology) In an open-label trial further investigating the use of CINRYZE for prevention (n=146) of HAE attacks, 5 serious thrombotic events (including myocardial infarction, deep vein thrombosis, pulmonary embolism and 2 events of cerebrovascular accident) occurred. Subjects had underlying risk factors for thrombotic events. Monitor closely patients with known risk factors for thrombotic events. 5.3 Transmissible Infectious Agents Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob (CJD) agent [11]. ALL infections thought by a physician possibly to have been transmitted by CINRYZE should be reported by the physician or other healthcare provider to ViroPharma Biologics, Inc. [(877) ]. The physician should discuss the risks and benefits of this product with the patient, before prescribing or administering it to the patient. (See Patient Counseling Information [17]) 6 ADVERSE REACTIONS The only serious adverse reaction observed in clinical studies of CINRYZE was cerebrovascular accident. The most common adverse reactions observed were headache, nausea, rash, and vomiting. As with all therapeutic proteins, there is potential for immunogenicity. Using a validated assay there was no evidence of antibody development following administration of CINRYZE. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of anti-c1 Esterase Inhibitor antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibody development across products cannot be made. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Routine Prophylaxis Twenty-four subjects were evaluated in the randomized, placebo-controlled, crossover, routine prophylaxis trial. There were no serious adverse reactions in the randomized, placebo-controlled, crossover, routine prophylaxis trial. Adverse reactions in the randomized, placebo-controlled, crossover, routine prophylaxis trial (n=24) that occurred in at least two subjects ( 8%) receiving CINRYZE are given in the following table: Table 2 Adverse Reactions in the Randomized, Placebo-Controlled, Crossover, Routine Prophylaxis Trial Adverse Reaction Number of Number of Adverse Reactions Subjects (N = 24) Rash 8 5 Headache 4 4 Pruritus 2 2 Vomiting 2 2 In an open-label follow-on trial, 146 patients received a median of days of CINRYZE (maximum = 959 days). The most common adverse reaction observed was headache. No patients were discontinued due to an adverse reaction. Adverse reactions in the open-label follow-on trial (n=146) that occurred in at least three subjects ( 2%) receiving CINRYZE, are given in the following table: Table 3 Adverse Reactions in the Open-Label Follow-On Trial Adverse Reaction Number (%) of Subjects (N=146) with Adverse Reaction Number (%) of Infusion Days (N=11,435) with Adverse Reaction Headache 28 (19) 62 (0.5) Nausea 26 (18) 29 (0.3) Rash 15 (10) 30 (0.3) Vomiting 15 (10) 17 (0.1) Pyrexia 7 (5) 7 (<0.1) Catheter Site Pain 4 (3) 5 (<0.1) Dizziness 3 (2) 4 (<0.1) Erythema 3 (2) 3 (<0.1) Pruritus 3 (2) 4 (<0.1) More than 14,000 doses of CINRYZE have been administered to over 260 different patients in all completed, controlled and open-label clinical studies. All patients who were evaluated were found negative for seroconversion to parvovirus B19, Hepatitis B, Hepatitis C and HIV. 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Postmarketing adverse reactions include local infusion site reactions (including pain, rash, erythema, inflammation or hematoma at the infusion site). Postmarketing thrombotic events have been reported, including catheter-related and deep venous thromboses, transient ischemic attack, and stroke. Patients with known risk factors for thrombotic events should be monitored closely. (See Section 5.2 Thrombotic events in WARNINGS AND PRECAUTIONS) 7 DRUG INTERACTIONS No drug interaction studies have been conducted. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category C. No animal data are available. No adequate and well-controlled studies were conducted in pregnant women. It is not known whether CINRYZE can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CINRYZE should be given to a pregnant woman only if clearly needed. 8.2 Labor and Delivery The safety and effectiveness of CINRYZE administration prior to or during labor and delivery have not been established. Use only if clearly needed. 8.3 Nursing Mothers It is not known whether CINRYZE is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CINRYZE is administered to a nursing woman. 8.4 Pediatric Use The safety and effectiveness of CINRYZE have not been established in neonates, infants, or children. Three of the 24 subjects in the randomized, placebo-controlled, crossover, routine prophylaxis trial, were under the age of 18 years (9, 14, and 16 years of age). 8.5 Geriatric Use The randomized, placebo-controlled, crossover, routine prophylaxis trial did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger subjects. 10 OVERDOSAGE The maximum dose administered in clinical studies was 4000 Units given over approximately 5 hours (an average dose of 57 Units/kg) and 9000 Units given over a 7 day period. There have been no overdosages of CINRYZE reported during clinical studies. In vitro and in vivo animal thrombogenicity studies with CINRYZE showed a potential for clot formation when CINRYZE was administered at doses 14 times the recommended clinical dose (greater than 200U/kg). Thrombotic events have been reported in association with C1 esterase inhibitor products when used off-label at high doses. 2 Animal studies have supported a concern about the risk of thrombosis from intravenous administration of C1 esterase inhibitor products. 3 (See Section 13.2 Animal Toxicology and/or Pharmacology and Section 5.2 Thrombotic events in WARNINGS AND PRECAUTIONS) 11 DESCRIPTION CINRYZE (C1 esterase inhibitor [human]) is a sterile, stable, lyophilized preparation of C1 esterase inhibitor derived from human plasma. CINRYZE is manufactured from human plasma purified by a combination of filtration and chromatographic procedures. The specific activity of CINRYZE is units/mg protein. The purity is 90% human C1 esterase inhibitor. Following reconstitution with 5 ml of Sterile Water for Injection, USP, each vial contains approximately 500 units of functionally active C1 esterase inhibitor, ph , and an osmolality between mosmol/kg. One Unit (U) of CINRYZE corresponds to the mean quantity of C1 esterase inhibitor present in 1 ml of normal fresh plasma. CINRYZE, when reconstituted with 5 ml of Sterile Water for Injection, USP contains the following excipients: 4.1 mg/ml sodium chloride, 21 mg/ml sucrose, 2.6 mg/ml trisodium citrate, 2.0 mg/ml L-Valine, 1.2 mg/ml L-Alanine, and 4.5 mg/ml L-Threonine. The following manufacturing steps are designed to reduce the risk of viral transmission: Screening donors at U.S. licensed blood collection centers to rule out infection with Human Immunodeficiency Virus (HIV-1/HIV-2), Hepatitis B Virus, or Hepatitis C Virus. Testing plasma pools by in-process NAT for parvovirus B19 via minipool testing and the limit of B19 in the manufacturing pool is set not to exceed 10 4 IU of B19 DNA per ml. Use of two independent viral reduction steps in the manufacture of CINRYZE: pasteurization (heat treatment at 60 C for 10 hours in solution with stabilizers) and nanofiltration through two sequential 15 nm filters. These viral reduction steps, along with a step in the manufacturing process, PEG precipitation, have been validated in a series of in vitro experiments for their capacity to inactivate/remove a wide range of viruses of diverse physicochemical characteristics including: Human Immunodeficiency Virus (HIV), Hepatitis A Virus (HAV), and the following model viruses: Bovine Viral Diarrhea Virus (BVDV) as a model virus for HCV, Canine Parvovirus (CPV) as a model virus for Parvovirus B19, Pseudorabies Virus (PRV) as a model virus for large enveloped DNA viruses (e.g. herpes virus). Total mean log 10 reductions are shown in Table 4. Table 4 Log 10 Virus Reduction Factor for Selected Viruses Log 10 Virus Reduction Process step Enveloped viruses Non-enveloped viruses HIV BVDV PRV HAV CPV PEG precipitation 5.1 ± ± ± ± ± 0.2 Pasteurization > 6.1 ± 0.2 > 6.7 ± 0.3 > 6.7 ± ± ± 0.3 Nanofiltration > 5.6 ± 0.2 > 5.5 ± 0.2 > 6.4 ± 0.3 > 4.9 ± 0.2 > 4.5 ± 0.3 Total reduction > 16.8 > 16.7 > 19.1 > 10.5 > CLINICAL PHARMACOLOGY 12.1 Mechanism of Action C1 inhibitor is a normal constituent of human blood and is one of the serine proteinase inhibitors (serpins). The primary function of C1 inhibitor is to regulate the activation of the complement and intrinsic coagulation (contact system) pathway. C1 inhibitor also regulates the fibrinolytic system. Regulation of these systems is performed through the formation of complexes between the proteinases and the inhibitor, resulting in inactivation of both and consumption of the C1 inhibitor. HAE patients have low levels of endogenous or functional C1 inhibitor. Although the events that induce attacks of angioedema in HAE patients are not well defined, it is thought by some that increased vascular permeability and the clinical manifestation of HAE attacks are primarily mediated through contact system activation. Suppression of contact system activation by C1 inhibitor through the inactivation of plasma kallikrein and factor XIIa is thought to modulate this vascular permeability by preventing the generation of bradykinin 1. Administration of CINRYZE increases plasma levels of C1 inhibitor activity Pharmacodynamics In clinical studies, the intravenous administration of CINRYZE demonstrated an increase in plasma levels of C1 inhibitor within approximately one hour or less of administration. Biological activity of CINRYZE was shown in 35 subjects by the subsequent increase in plasma C4 levels from an average of C4 8.1 mg/ml at baseline to C4 8.6 mg/ml 12 hours after infusion of CINRYZE.
14 12.3 Pharmacokinetics A randomized, parallel group, open-label pharmacokinetics (PK) study of CINRYZE was performed in patients with non-symptomatic hereditary angioedema (HAE). The patients received either a single dose of 1,000 Units or 1,000 Units followed by a second 1,000 Units 60 minutes later. The PK results for functional C1 inhibitor are presented the following table: Table 5 Mean pharmacokinetic parameters of Functional C1 Inhibitor Parameters Single Dose Double Dose C baseline (units/ml) 0.31 ± 0.20 (n = 12) 0.33 ± 0.20 (n = 12) C max (units/ml) 0.68 ± 0.08 (n = 12) 0.85 ± 0.12 (n = 13) T max (hrs) 3.9 ± 7.3 (n = 12) 2.7 ± 1.9 (n = 13) AUC (0-t) (units*hr/ml) 74.5 ± 30.3 (n = 12) 95.9 ± 19.6 (n = 13) CL (ml/min) 0.85 ± 1.07 (n = 7) 1.17 ± 0.78 (n = 9) Half-life (hours) 56 ± 36 (n = 7) 62 ± 38 (n = 9) Numbers in parenthesis are number of subjects evaluated Single dose = 1,000 Units Double dose = 1,000 Units followed by a second 1,000 Units 60 minutes later * One Unit is equal to the mean C1 inhibitor concentration of 1 ml of normal human plasma The maximum plasma concentrations (Cmax) and area under the plasma concentrationtime curve (AUC) increased from the single to double dose, although the increase was not dose proportional. The mean half-lives of CINRYZE were 56 hours (range 11 to 108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose. Studies have not been conducted to evaluate the PK of CINRYZE in special patient populations identified by gender, race, age (pediatric or geriatric), or the presence of renal or hepatic impairment. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No animal studies have been completed to evaluate the effects of CINRYZE on carcinogenesis, mutagenesis, and impairment of fertility Animal Toxicology and/or Pharmacology Acute toxicity of CINRYZE was studied in a combined acute toxicity and 7-day repeat dose/ dose range finding (DRF) study in Sprague Dawley rats. Repeat dose toxicity was studied in a 7-day repeat dose follow up to the acute dose study. The acute and repeated dose toxicity studies were performed with intravenous administration of CINRYZE at dose levels of 1, 7 and 28 times normal dose. No signs of toxicity were observed in the single dose study. In the repeated dose study, no signs of toxicity were observed in the two lower doses. Repeat dosing in the rat resulted in a robust neutralizing antibody response between days 1 and 14. Therefore, toxicity in animals dosed repeatedly is difficult to interpret. In vitro and in vivo thrombogenicity studies showed a potential for clot formation when CINRYZE was administered at doses 14 times the recommended clinical dose (greater than 200U/kg). 14 CLINICAL STUDIES The safety and efficacy of CINRYZE prophylaxis therapy to reduce the incidence, severity, and duration of HAE attacks was demonstrated in a single randomized, double blind, placebo controlled multi-center cross-over study of 24 patients. Patients were screened to confirm a diagnosis of HAE and a history of at least two HAE attacks per month. 24 patients (mean age 38.1 years with a range of 9 to 73 years) were randomized to one of two treatment groups: either CINRYZE prophylaxis for 12 weeks followed by 12 weeks of placebo prophylaxis; or randomized to placebo prophylaxis for 12 weeks followed by 12 weeks of CINRYZE prophylaxis. Two subjects dropped out (one in each arm); 22 patients crossed over into period 2 and were included in the efficacy analysis. Patients were given blinded injections (CINRYZE or placebo) every 3 to 4 days, approximately 2 times per week. Patients recorded all angioedema symptoms daily. An attack was defined as the subject-reported indication of swelling at any location following a report of no swelling on the previous day. The efficacy determination was based on the number of attacks during the 12 week period while receiving CINRYZE as compared to the number of attacks during the placebo treatment period. The effectiveness of C1 esterase inhibitor prophylaxis in reducing the number of HAE attacks was variable among the subjects as shown in table 6: Table 6 The Randomized, Placebo-Controlled, Crossover, Routine Prophylaxis Trial: Prevention of HAE Attacks Clinical Trial Results by Subject Percent Reduction Subject in Attack Frequency 1 100% 2 100% 3 100% 4 100% 5 90% 6 88% 7 84% 8 83% 9 78% 10 76% 11 60% 12 47% 13 43% 14 43% 15 32% 16 31% 17 25% 18 21% 19 10% 20 1% 21-8% 22-85% Table 7 Summary Statistics on Number of HAE Attacks in the Randomized, Placebo-Controlled, Crossover, Routine Prophylaxis Trial Statistic CINRYZE N=22 Placebo N=22 Mean SD Number Median of Attacks Min 0 6 Max GEE Analysis Results Effect Assessed p-value Treatment Effect < Sequence Effect Period Effect Patients treated with CINRYZE had a 66% reduction in days of swelling (p<0.0001), and decreases in the average severity of attacks (p=0.0006) and the average duration of attacks (p=0.0023), as shown in table 8. Table 8 The Randomized, Placebo-Controlled, Crossover, Routine Prophylaxis Trial: Secondary Efficacy Outcomes Mean Severity of HAE Attacks (Score from 1 to 3) 1 (SD) Mean Duration of HAE Attacks (Days) (SD) Days of Swelling (SD) CINRYZE N=22 1 1=mild; 2=moderate; and 3=severe **p<0.01 Placebo N= (0.85) 1.9 (0.36) 2.1 (1.13) 3.4 (1.4) 10.1 (10.73) 29.6 (16.9) 95% Confidence Interval for Treatment Effect (Placebo minus CINRYZE) 0.58** (0.19, 0.97) 1.23** (0.49, 1.96) 19.5** (11.94, 27.06) 15 REFERENCES 1. Davis AE, The pathophysiology of hereditary angioedema. Clin Immunol. 2005; 114: Arzneimittelkommission der Deutschen Aertzteschaft. Schwerwiegende Thrombenbildung nach Berinert HS. Dtsch Aerztebl. 2000; 97:B Horstick, G et al, Circulation 104: HOW SUPPLIED/STORAGE AND HANDLING CINRYZE is a lyophilized powder that is supplied in a vacuum-sealed vial. CINRYZE is available in single-use vials that contain 500 Units per vial. CINRYZE is supplied as a single glass vial of CINRYZE powder to be reconstituted with 5 ml Sterile Water for Injection, USP (Not supplied). CINRYZE, packaged for sale, is stable for 24 months when stored at 2 C 25 C (36 F-77 F). Do not freeze. Store the vial in the original carton to protect it from light. The reconstituted solution must be used within 3 hours of reconstitution. Do not use beyond the expiration date on the vial of CINRYZE. 17 PATIENT COUNSELING INFORMATION 17.1 Allergic-type Hypersensitivity Reactions Allergic-type hypersensitivity reactions are possible [5.1]. Inform patients of the early signs of hypersensitivity reactions [including hives (itchy white elevated patches), tightness of the chest, wheezing, hypotension] and anaphylaxis. Advise patients to discontinue use of CINRYZE and contact their physicians if these symptoms occur Pregnancy Advise female patients to notify their physician if they become pregnant or intend to become pregnant during their routine prevention with CINRYZE Nursing Advise patients to notify their physician if they are breastfeeding or plan to breastfeed Usage While Traveling Based on their current regimen, advise patients to bring an adequate supply of CINRYZE for routine prevention when traveling. Advise patients to consult with their healthcare professional prior to travel Transmissible Infectious Agents Advise patient that, because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt- Jakob (CJD) agent [5.3, 11]. The risk of transmitting disease has been reduced, but not eliminated, by carefully selecting blood donors, testing donors for infections, and inactivating or removing most viruses during the manufacturing process. Inform patients of the risks and benefits of CINRYZE before prescribing or administering to the patient. FDA-Approved Patient Labeling Information for the Patient CINRYZE (SIN-rise) (C1 Esterase Inhibitor [Human]) This leaflet summarizes important information about CINRYZE. Please read it carefully before using CINRYZE and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about CINRYZE. If you have any questions after reading this, ask your healthcare provider. Do not attempt to self-administer unless you have been taught how by your healthcare provider. What is CINRYZE? CINRYZE is an injectable medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE). HAE is caused by the decreased functioning of a protein called C1 esterase inhibitor, that is present in your blood and helps control inflammation (swelling) and parts of the immune system. CINRYZE contains C1 esterase inhibitor. Before you can inject CINRYZE into your vein (intravenous injection), you must dissolve the CINRYZE powder using Sterile Water for Injection, USP. You can get supplies, including Sterile Water for Injection, USP from your pharmacist. Who should not use CINRYZE? You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product. What should I tell my healthcare provider before using CINRYZE? Tell your healthcare provider about all of your medical conditions, including if you are pregnant or planning to become pregnant. It is not known if CINRYZE can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if CINRYZE passes into your milk and if it can harm your baby. have a history of blood clotting problems. Very high doses of C1 esterase inhibitor could increase the risk of blood clots. Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies. What are the possible side effects of CINRYZE? Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing difficulty breathing chest tightness turning blue (look at lips and gums) fast heartbeat swelling of the face faintness rash hives The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You can also report side effects to the FDA at FDA You can ask your healthcare provider for information that is written for healthcare providers. How should I store CINRYZE? Do not freeze CINRYZE. Store CINRYZE in a refrigerator or at room temperature between 36 to 77 F (2 to 25 C). Keep CINRYZE in the original carton to protect it from light. Do not use CINRYZE after the expiration date on the vial. After preparing CINRYZE, you can store it at room temperature for up to 3 hours. If you have not used it within 3 hours, throw it away. Only use the dissolved CINRYZE if it is colorless to slightly blue, clear and free from visible particles. What else should I know about CINRYZE? Medicines are sometimes prescribed for purposes other than those listed here. Do not use CINRYZE for a condition for which it is not prescribed. Do not share CINRYZE with other people, even if they have the same symptoms that you have. Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob (CJD) agent. This leaflet summarizes the most important information about CINRYZE. If you would like more information, talk to your healthcare provider. You can ask your healthcare provider or pharmacist for information about CINRYZE that was written for healthcare professionals. Instructions for Use Do not attempt to self-administer unless you have been taught how by your healthcare provider. See the step-by-step instructions for injecting CINRYZE at the end of this leaflet. You should always follow the specific instructions given by your healthcare provider. The steps listed below are general guidelines for using CINRYZE. If you are unsure of the steps, please call your healthcare provider or pharmacist before using. Call your healthcare provider right away if swelling is not controlled after using CINRYZE. Your healthcare provider will prescribe the dose that you should take. Call your healthcare provider if you take too much CINRYZE. Call your healthcare provider if you miss a dose of CINRYZE. Talk to your healthcare provider before traveling. You should plan to bring enough CINRYZE for your treatment during this time. Preparation of CINRYZE Always wash your hands before doing the following steps. Try to keep everything clean and germ-free while you are reconstituting CINRYZE. Once you open the vials, you should finish preparing CINRYZE as soon as possible. This will help to keep them germ-free. CINRYZE IS A FREEZE-DRIED POWDER THAT IS SUPPLIED IN A VACUUM-SEALED VIAL. Note: Two vials of CINRYZE are required for each dose. You should reconstitute both vials according to steps 1 through Let the vial of CINRYZE and the vial of Sterile Water for Injection, USP (diluent) reach room temperature. 2. Remove the cap from the vial of CINRYZE and Sterile Water for Injection, USP (diluent) vial to show the center part of the rubber stopper. 3. Wipe the top of each vial with an alcohol wipe or swab, and allow it to dry. Do not blow on the stopper to dry it faster. Place each vial on a flat surface. After cleaning, do not touch the rubber stopper with your hand or allow it to touch any surface. 4. Note: Diluent vial must be penetrated before the CINRYZE vial to prevent loss of vacuum. Remove the protective covering from the top of the Mix2Vial transfer device package. Do not remove the device from the package. Place the Sterile Water for Injection, USP (diluent) vial on a flat surface, and place the blue end of the Mix2Vial transfer device over it, pushing down until the spike penetrates the rubber stopper and the device snaps in place. Mix2Vial transfer device must be positioned completely upright before penetrating the rubber stopper. Remove the plastic package and discard it. Take care not to touch the exposed end of the device. 5. Place the vial of CINRYZE on a flat surface. Turn the diluent vial containing 5 ml Sterile Water for Injection, USP, upside-down and insert the clear end of the Mix2Vial transfer device into the vial of CINRYZE, pushing down until the spike penetrates the rubber stopper and the device snaps in place. The Mix2Vial transfer device must be positioned completely upright before penetrating the rubber stopper. The Sterile Water for Injection, USP, will automatically flow into the vial of CINRYZE because the vacuum in the vial will draw the Sterile Water for Injection, USP, into the vial of CINRYZE. If this does not happen, do not use the product. 6. Once all the Sterile Water for Injection, USP, is in the CINRYZE vial, gently swirl (do not shake) the vial of CINRYZE until all the powder is dissolved. Disconnect the Sterile Water for Injection, USP vial by turning it counterclockwise. Do not remove the clear end of the Mix2Vial transfer device from the vial of CINRYZE. Look at the final solution before using it to make sure that CINRYZE is completely dissolved. Once dissolved, the solution in the vial of CINRYZE should be colorless to slightly blue and clear. Do not use the product if the solution is cloudy, discolored or contains any particles. Throw it away and prepare a new vial of CINRYZE. One vial of dissolved CINRYZE contains 5 ml of C1 esterase inhibitor at a concentration of 100 Units/mL. Prepare two vials of CINRYZE for one dose. Repeat steps 1-6 using a new Mix2Vial transfer device. Do not reuse the Mix2Vial transfer device. 7. Utilizing a sterile, disposable 10mL syringe, draw back the plunger to allow approximately 5mL of air into the syringe. 8. Attach the syringe onto the clear end of the Mix2Vial transfer device by turning it clockwise. 9. Turn the vial of CINRYZE upside down, inject air into the vial. Slowly pull as much dissolved CINRYZE as possible into the syringe. While holding the vial upside down, detach the syringe from the vial by turning it counterclockwise and releasing it from the Mix2Vial transfer device. Remove any air bubbles by gently tapping the syringe with your finger and slowly pushing the air out of the syringe. Repeat steps 7-9 above with a second vial of CINRYZE to make one complete dose of 10 ml. 10. Dispose of the vials with the Mix2Vial transfer device attached to them. CINRYZE should be administered within 3 hours after preparation. The dissolved CINRYZE solution may be stored at room temperature prior to administration. If not used within 3 hours after preparation, throw away the CINRYZE solution. SELF ADMINISTRATION (Intravenous Injection) Your healthcare provider will teach you how to safely administer CINRYZE. It is important that CINRYZE is injected directly into a superficial vein and not injected into surrounding tissues and not injected into an artery. Once you learn how to self-administer, you can follow the instructions in this insert. 1. Attach a needle or infusion set with a winged adapter to the syringe containing the dissolved CINRYZE solution. Fill the tubing with dissolved CINRYZE by gently pushing the plunger of the syringe. Be careful not to spill the dissolved CINRYZE. This process replaces the air in the tubing with dissolved CINRYZE. 2. Apply a tourniquet and prepare the injection site by wiping the skin well with an alcohol swab. 3. As instructed by your healthcare provider: Insert the butterfly needle of the infusion set tubing into your vein. Remove the tourniquet. Make sure that the needle is in a vein. Inject the dissolved CINRYZE product slowly over ten minutes (approximately 1mL/min). 4. After infusing CINRYZE, remove the infusion set and discard. Cover infusion site with an adhesive bandage. The amount of drug product left in the infusion set will not affect your treatment. Dispose of all unused solution, the empty vials, and the used needles and syringe in an appropriate container used for throwing away waste that might hurt others if not handled properly. It is a good idea to record the lot number from the CINRYZE vial label every time you use CINRYZE. This Patient Package Insert has been approved by the U.S. Food and Drug Administration. Manufactured by: Sanquin Blood Supply Foundation Amsterdam, The Netherlands Distributed by: ViroPharma Biologics, Inc. Exton, PA U.S. License Number 1833 Mix2Vial is a registered trademark of Medimop Medical Projects, Ltd. in the United States and other jurisdictions. CINRYZE is a trademark of ViroPharma Incorporated or its subsidiaries ViroPharma Incorporated. All rights reserved. DD /2012
RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS
RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS TRUST THE POWER OF PREVENTION WITH CINRYZE Whether your patients are new to treatment or are continuing their journey, remind
More informationRECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS. Hereditary Angioedema
RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS Hereditary Angioedema TRUST PROVEN PREVENTION WITH CINRYZE Whether your patients are new to treatment or are continuing their
More informationPREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS
PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS Hereditary Angioedema Jenny, a real HAE patient TAKE CONTROL OF YOUR HEREDITARY ANGIOEDEMA (HAE) TREATMENT WITH SELF-ADMINISTRATION Choosing
More informationPREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS
PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS Hereditary Angioedema TAKE CONTROL OF HEREDITARY ANGIOEDEMA (HAE) TREATMENT WITH FLEXIBLE ADMINISTRATION Choosing to treat with CINRYZE (C1
More informationWHY IS PREVENTION IMPORTANT?
A GUIDE TO TRUST THE POWER OF PREVENTION < 2 > WHY IS PREVENTION IMPORTANT? Hereditary angioedema (HAE) symptoms can range in severity. Some attacks may be mild or temporarily disabling, but others can
More informationSTAYING ON TRACK WITH CINRYZE THERAPY
YOUR GUIDE TO STAYING ON TRACK WITH CINRYZE THERAPY Indication CINRYZE (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks
More informationCSL Behring PACKAGE LEAFLET: INFORMATION FOR THE USER
CSL Behring PACKAGE LEAFLET: INFORMATION FOR THE USER Berinert 500 IU Powder and solvent for solution for injection / infusion Berinert 1500 IU Powder and solvent for solution for injection Human C1-esterase
More informationCinryze. Cinryze (C1 esterase inhibitor [human]) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze
More informationRECOMBINATE. [Antihemophilic Factor (Recombinant)] (For intravenous use only)
Website for more information: http://www.recombinate.com/ INSTRUCTIONS FOR USE RECOMBINATE [Antihemophilic Factor (Recombinant)] (For intravenous use only) Do not attempt to do an infusion to yourself
More informationBerinert [C1 Esterase Inhibitor (Human)] For intravenous use. Freeze-Dried Powder for Reconstitution. Initial U.S. Approval: 2009
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Berinert safely and effectively. See full prescribing information for Berinert. Berinert [C1 Esterase
More informationPrescribing BERINERT: An Instructional Guide
Prescribing BERINERT: An Instructional Guide BERINERT is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE)
More informationTEV-TROPIN [somatropin (rdna origin) for injection] 5 mg & 10 mg
TEV-TROPIN [somatropin (rdna origin) for injection] 5 mg & 10 mg TEV-TROPIN (somatropin for injection) Information for the Patient or Parent Read all instructions before proceeding. Do not mix (reconstitute)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationplan prepare progress
plan prepare progress Hereditary Angioedema (HAE) Treatment Plan and Therapy Journal Plan, prepare, and personalize an effective treatment plan for your HAE attacks Share your progress with your healthcare
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationPanzyga Administration Guide
Immune Human Normal Globulin Immunoglobulin Intravenous (Human) (IVIg) Octapharma s new Intravenous Immunoglobulin (IVIG) Panzyga Administration Guide An educational service tool provided by Octapharma
More informationDilution Sequence Protocol
Dilution Sequence Protocol ATS Short Quadrupling Doses 0.0625 0.25 1 4 16 Provocholine 1600 mg/vial (US NDC 64281-016-01) 1 Provocholine (methacholine chloride USP) powder for solution, for inhalation,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218
More informationDilution Sequence Protocol
Dilution Sequence Protocol US Package Insert Multi-Patient (2-5 patients; requires 2 vials of Provocholine) 0.025 0.25 2.5 10 25 Provocholine 100 mg/vial (US NDC 64281-100-06) 1 Provocholine (methacholine
More informationDilution Sequence Protocol
Dilution Sequence Protocol ATS Short Quadrupling Doses 0.0625 0.25 1 4 16 Provocholine 100 mg/vial (US NDC 64281-100-06) 1 Provocholine (methacholine chloride USP) powder for solution, for inhalation,
More informationRUCONEST - conestat alfa injection, powder, for solution Santarus, Inc
RUCONEST - conestat alfa injection, powder, for solution Santarus, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RUCONEST safely
More informationANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ruconest 2100 U powder for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 2100 units
More informationAseptic Techniques. Techniques for Sterile Compounding. Pharmacy Technician Training Systems Passassured, LLC
Aseptic Techniques Techniques for Sterile Compounding Pharmacy Technician Training Systems Passassured, LLC Aseptic Techniques, Tech for Sterile Compounding PassAssured's Pharmacy Technician Training Program
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Ruconest 2100 U powder for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 2100 units
More informationMixing Methacholine Dilutions for Bronchoprovocation Challenge Testing
powder for solution, for inhalation Mixing Methacholine Dilutions for Bronchoprovocation Challenge Testing Provocholine is a registered trademark of Methapharm Inc. Copyright Methapharm Inc. 2016. All
More informationSubject: Hereditary Angioedema Drug Therapy
09-J1000-08 Original Effective Date: 07/15/09 Reviewed: 01/09/18 Revised: 02/15/19 Subject: Hereditary Angioedema Drug Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationPublic Assessment Report. Berinert. C1-Esterase-Inhibitor, human DE/H/0481/001/MR. Applicant: CSL Behring GmbH. Date of Report:
Public Assessment Report Berinert C1-Esterase-Inhibitor, human DE/H/0481/001/MR Applicant: CSL Behring GmbH Date of Report: 02.02.2009 This module reflects the scientific discussion for the approval of
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationTREATMENT GUIDE. Your treatment. Your questions answered.
TREATMENT GUIDE Your treatment. Your questions answered. INDICATIONS: Kineret is a prescription medicine called an interleukin-1 receptor antagonist (IL-1ra) used to: Reduce the signs and symptoms, and
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationNote: Does have indication for Prophy- suggest 25 units/kg every other day
Recombinant Factor VIII Helixate (CSL): Vial Sizes: 250,500, 1000, 2000, 3000 2.5ml 5ml 2000 s & 3,000 s Administer within 3 hours of reconstitution. A dose of Helixate may be administered over a period
More informationPatients Guide for Self Administering Intravenous Antibiotics General points
Patients Guide for Self Administering Intravenous Antibiotics General points An intravenous line is an open route for infection therefore you need to prevent this by washing your hands before any procedure
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Exembol Multidose 100 mg/ml concentrate for solution for infusion. Argatroban Monohydrate
PACKAGE LEAFLET: INFORMATION FOR THE USER Exembol Multidose 100 mg/ml concentrate for solution for infusion Argatroban Monohydrate Read all of this leaflet carefully before you start using this medicine.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBefore you use KINERET. When you must not use it. Do not use KINERET if you have. using a medicine known as tumour necrosis factor (TNF) antagonist.
KINERET anakinra Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about KINERET. It does not contain all the available information. It does not take the
More informationBefore you use. When you must not use it
anakinra Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about KINERET. It does not contain all the available information. It does not take the place of
More informationVarithena Delivery System Instructions for Use INSTRUCTIONS FOR USE Please read the Product Monograph before using the product.
Varithena Delivery System Instructions for Use INSTRUCTIONS FOR USE Please read the Product Monograph before using the product. The Instructions for Use are for the entire Varithena TM system. There are
More informationVarithena Delivery System Instructions for Use
Varithena Delivery System Instructions for Use Please read all prescribing information before using the product. The Instructions for Use are for the entire Varithena system. There are 2 packaging configurations:
More informationIVIG Educational Presentation
IVIG Educational Presentation Administration of IVIG direct from the Bottle Note: This is not the procedure please refer to the procedure in epops 16/06/2017 IVIG Administion from a bottle 1 Change in
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human, Recombinant) Reference Number: CP.CPA.76 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of
More informationVenepuncture. Clinical Skills. Venepuncture. Dr Brian Jenkins (Clinical Skills Lead) Sian Williams (Clinical Skills Manager)
Clinical Skills Venepuncture Dr Brian Jenkins (Clinical Skills Lead) Sian Williams (Clinical Skills Manager) Aims and Objectives Aims and Objectives The aim of this module is to facilitate learning regarding
More informationBlood Pressure Monitoring: Arterial Line
Approved by: Blood Pressure Monitoring: Arterial Line Gail Cameron Senior Director, Operations, Maternal, Neonatal & Child Health Programs Dr. Ensenat Medical Director, Neonatology Neonatal Nursery Policy
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationHemoCue Hb Procedure Template
HemoCue Hb 201 + Procedure Template PURPOSE The HemoCue Hb 201 + System is used for the quantitative determination of hemoglobin in blood using a specially designed analyzer, HemoCue Hb 201 +, and specially
More information3. This solution retains potency for 2 8 hours at room temperature after reconstitution.
1 CHAPTER 10 Reconstitution of Powdered Drugs Problems 10.1 (page 124) 1. The drug should be stored at or below 86 F (30 C). 2. This drug is administered IM or IV. 3. This solution retains potency for
More informationAssisting with Insertion. Care of Intraspinal Catheters
Guidelines included: Assisting with an Insertion Care of Various types of Intraspinal s Care of the Intraspinal Infusion Monitoring Removal of the Short Term Non Assisting with Insertion INR should be
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Ethambutol Hydrochloride Tablets USP 100 mg and 400 mg Lupin Limited Mumbai 400 098 INDIA
More informationBerinert. 1. Identification. Page 1 of 8. SDS Date: 04/04/2017
IMPORTANT NOTICE: This Safety Data Sheet (SDS) is prepared by CSL Behring in accordance with Safe Work Australia National Code of Practice for the Preparation of Safety Data Sheets (February 2016). The
More informationhelping patients thrive Clotting Factor Concentrate Information
helping patients thrive Clotting Factor Concentrate Information LEGEND: VWF Von Willebrand factor Plasma derived IU International unit RCo Ristocetin cofactor ml Milliliter mg Milligram clotting factor
More informationKcentra SDS Revision Date: 06/03/2015
1. Identification 1.1. Product identifier Product Identity Alternate Names Kcentra Kcentra 1.2. Relevant identified uses of the substance or mixture and uses advised against Intended use Application Method
More informationSAFETY DATA SHEET (SDS) SDS 093 Revision number: 1 Rev. 11/17. Calibrator 80 Low/High Part Numbers: For use with the ADAMS A1c HA-8180V
SAFETY DATA SHEET (SDS) Revision date: SDS 093 Revision number: 1 Rev. 11/17 Calibrator 80 Low/High Part Numbers: 103400 For use with the ADAMS A1c HA-8180V ARKRAY USA, Inc. 5182 West 76 th Street Minneapolis,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/He AGA 0.28%, 9.3% medicinal gas, compressed
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/He AGA 0.28%, 9.3% medicinal gas, compressed 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Carbon monoxide (CO) 0.28% under
More informationPreludeSYNC. Radial Compression Device INSTRUCTIONS FOR USE
PreludeSYNC Radial Compression Device INSTRUCTIONS FOR USE PreludeSYNC Radial Compression Device English INSTRUCTIONS FOR USE PRODUCT DESCRIPTION The Prelude Sync Radial Compression Device is a sterile,
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride)
PACKAGE LEAFLET: INFORMATION FOR THE USER FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride) Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationMaterial Safety Data Sheet
Material Safety Data Sheet HEPATOLITE Revised 03-Jul-2008 Issued 02-NOV-2006 --------------------------------------------------------------------------------------------------------------------------------
More informationUSP <797> LABELING ESTABLISHING BEYOND-USE DATES AND IN-USE TIMES
USP LABELING ESTABLISHING BEYOND-USE DATES AND IN-USE TIMES Each CSP label must state the date beyond which the preparation cannot be used and must be discarded. A CSP may also be labeled with an
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Lamisil 1 % cutaneous spray solution Terbinafine hydrochloride
The PL includes alternative texts for different legal status in different countries as follows: - Boxed texts are only applicable for OTC versions. - [Grey-shaded texts in brackets] are only applicable
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lung test gas, CO/C 2 H 2 /CH 4 AGA 0.3%, 0.3%, 0.3% medicinal gas, compressed 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Carbon monoxide
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Firazyr 30 mg solution for injection in pre-filled syringe 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe
More informationPUMP WITH FIXED FLOW RATE. Instructions for Use
PUMP WITH FIXED FLOW RATE Instructions for Use ON-Q* Pump with Fixed Flow Rate Instructions For Use Important Information Please read the entire document before operating the ON-Q* device. Follow all
More informationChapter 40. Fluid, Electrolyte, and Acid Base Balance. Procedures Checklist INTRAVENOUS THERAPY. Procedure 40.1: Starting an Intravenous Infusion
Procedures Checklist INTRAVENOUS THERAPY Chapter 40 Fluid, Electrolyte, and Acid Base Balance Procedure 40.1: Starting an Intravenous Infusion Performed Preparation Yes No Mastered Comments 1. Assess:
More informationPERFORMANCE OF A FINGERSTICK
PERFORMANCE OF A FINGERSTICK Follow the procedure as outlined above for greeting and identifying the patient. As always, properly fill out appropriate requisition forms, indicating the test(s) ordered.
More informationNursing Guide Portsystems
Quality and Experience Portsystems This nursing-guide is intended to answer general questions concerning port catheter systems. All other questions should be addressed to your attending physician or nursing
More informationCspB ELISA Kit DAS ELISA for the detection of CspB protein Catalog number: PSP 35500
List of contents Lot number Item 480 wells 4800 wells Antibody-coated 96-well microtiter plates 5 strip 50 solid Peroxidase enzyme conjugate, concentrated 0.550 ml 5 x 1.1 ml RUB6 enzyme conjugate diluent
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Hereditary Angioedema (HAE) Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective
More informationUpdate on recent trials in the treatment of hereditary angioedema
Review: Clinical Trial Outcomes Update on recent trials in the treatment of hereditary angioedema Clin. Invest. (2011) 1(3), 439 445 Hereditary angioedema (HAE) is a rare genetic condition that manifests
More informationBt-Cry1Ac & Bt-Cry2A Multi-trait ELISA Kit DAS ELISA for the detection of Bt-Cry1Ac & Bt-Cry2A proteins Catalog number: PSM 14900
List of contents Lot number Item 480 wells 4800 wells Antibody-coated 96-well microtiter plates 5 strip 50 solid Alkaline phosphatase enzyme conjugate, concentrated 0.550 ml 5 x 1.1 ml Peroxidase enzyme
More informationObjectives: Assisting with Medication, Checking vital Signs
Assisting with Medication, Checking vital Signs Duty: Assist Client with Personal Hygiene Task : A.12 Remind client to take medication A.17 Check client s temperature A.18 Check client s pulse A.19 Check
More informationCounty of Santa Clara Emergency Medical Services System
County of Santa Clara Emergency Medical Services System Policy # 700-S01 Ebola Virus Prevention and Control EBOLA VIRUS PREVENTION AND CONTROL Effective: October 30, 2014 Replaces: October 8, 2014 (Version
More informationMATERIAL SAFETY DATA SHEET
Product Name: Sedia HIV-1 LAg-Avidity EIA Catalog Number: 1002 Company: Sedia Biosciences Corp. 4900 NE 122 nd Ave. Email: customerservice@sediabio.com Phone: +1-503-459-4159 Fax: +1-503-459-4168 The Sedia
More informationChapter 37 (pages ): Hereditary Angioedema and Bradykinin-Mediated Angioedema Prepared by: Sarah Spriet, DO
FIT Board Review Corner May 2017 Welcome to the FIT Board Review Corner, prepared by Tammy Peng, MD, and Amar Dixit, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the Board
More informationMATERIAL SAFETY DATA SHEET SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION NOBIVAC LEPTO4
Merck Animal Health One Merck Dr. Whitehouse Station, NJ 08889 MATERIAL SAFETY DATA SHEET Merck Animal Health urges each user or recipient of this MSDS to read the entire data sheet to become aware of
More informationF7 (Human) Chromogenic Activity Assay Kit
F7 (Human) Chromogenic Activity Assay Kit Catalog Number KA0971 96 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the
More informationPHARMACOLOGY LABORATORY 2 PHARMACOKINETIC LABORATORY
PHARMACOLOGY LABORATORY 2 PHARMACOKINETIC LABORATORY OBJECTIVES: 1. Reinforce the different concepts of pharmacokinetics which were presented in lecture using computer simulation of one and multiple compartment
More informationCOLLECTION OF BLOOD. Types of patients
COLLECTION OF BLOOD Capillary Sampling The specimen of choice for laboratory analysis is generally a venous specimen. For blood gas analysis, the specimen of choice originates from an arterial draw. When
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET BAYER HEALTHCARE LLC Biological Products Division 8368 US 70 West Clayton, NC 27520 TRANSPORTATION EMERGENCY NON-TRANSPORTATION CALL CHEMTREC... : (800) 424-9300 BAYER EMERGENCY
More informationASAHI Neurovascular Guide Wire
ASAHI Neurovascular Guide Wire AMK-DT244 Ver.1.00 / 11TS073 Legal manufacturer Consult instructions for use Do not use if package is damaged RX ONLY Caution: Federal (USA) Law restricts this device to
More informationClinician Guide. Baxter Elastomeric Devices. Promoting patient-centric care
Clinician Guide Baxter Elastomeric Devices Promoting patient-centric care Portfolio Overview Portfolio Overview Baxter Elastomeric Devices are non-electronic medication devices designed to provide ambulatory
More informationBt-Cry2Ab and Bt-Cry3Bb1 Multi-trait ELISA Kit DAS ELISA for the detection of Bt-Cry2Ab and Bt-Cry3Bb1 proteins Catalog number: PSM 26800
List of contents Lot number Item 480 wells 4800 wells Antibody-coated 96-well microtiter plates 5 strip 50 solid Alkaline phosphatase enzyme conjugate, concentrated 0.550 ml 5 x 1.1 ml Peroxidase enzyme
More informationA designated area will have been assigned for all blood specimens to be taken. All blood should then be taken in that area only.
Venepuncture No: 008D 1. Introduction Blood sampling is a necessary requirement to assess the biochemical and haematological profile of subjects who enter clinical research studies. Risks to the subject
More informationUS - OSHA SAFETY DATA SHEET
US - OSHA SAFETY DATA SHEET Issue Date 15-Apr-2015 Version 3 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING Product identifier Product Name Other means of identification
More informationSecond Quarter 2018 Results Call Corporate Update & Financial Results. August 7, 2018
Second Quarter 2018 Results Call Corporate Update & Financial Results August 7, 2018 Forward-Looking Statements BioCryst s presentation may contain forward-looking statements, including statements regarding
More informationHydrofluoric Acid SOP
Introduction Hydrofluoric acid (HF) has a number of chemical, physical, and toxicological properties, which make handling this material especially hazardous. Anhydrous HF is a clear, colorless, fuming,
More informationMaking Life Easier Easypump II
Making Life Easier Easypump II The elastomeric pump system for short- and long-term infusion therapy Elastomeric Infusion Systems Technical Guide Easypump II Disposable Elastomeric Infusion Pump System
More informationbiosensis Mouse CXCL10/IP-10 ELISA Kit Protocol
biosensis Mouse CXCL10/IP-10 ELISA Kit Protocol Catalogue No: BEK-2124-2P TABLE OF CONTENTS I Materials provided...2 II Equipment required but not supplied...2 III Technical hints....2 IV Storage of kit
More informationTitle of Manual: Specimen Collection Document Number: GPA.SPC.45.0
Capillary Blood Page 1 of 5 I. PURPOSE This procedure provides guidelines on the proper technique for collecting diagnostic capillary blood specimens via skin puncture or heel puncture (infant only). Blood
More informationSTANDARD OPERATING PROCEDURE ADVANCED INTRAVENOUS TRAINING ARM (S )
Page 1 of 27 1. Scope This Standard Operating Procedure (SOP) applies to the staff and students using the Advanced Intravenous Training Arm in the Pharmacy Practice Resource Unit (PPRU) at the Pharmacy
More information1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING
SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier NEOSTIGMINE SOLUTION FOR Details of the supplier of the safety data sheet : ASTRAZENECA PTY
More informationSpecimen Collection. Lead Screen Filter Paper Testing Dried Blood Spots (DBS) Laboratory Services February 2017
1 Specimen Collection Lead Screen Filter Paper Testing Dried Blood Spots (DBS) Laboratory Services February 2017 2 Agenda Why Use Lead Screen Filter Paper Testing? Before You Begin Collection Drying &
More informationGAZYVA(R) Vials (1,000 mg/40 ml)
Safety Data Sheet GAZYVA(R) Vials (1,000 mg/40 ml) SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code Synonyms GAZYVA(R)
More informationMultiplate Platelet Function Analyzer: An Overview
Multiplate Platelet Function Analyzer: An Overview The Multiplate is for research use only in the US and Canada Scope: This is a summary of most aspects of platelet function testing using the Multiplate
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHEALTH SERVICES CODE A.6 CATEGORY: RN - SNP
NURSING PROCEDURE TITLE ARTERIAL BLOOD SAMPLING (NEONATAL) A. Umbilical Catheter Blood Collection B. Radial Arterial Line CATEGORY: RN - SNP PURPOSE To obtain blood samples for laboratory analysis NURSING
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPRODUCT SAFETY DATA SHEET
PRODUCT SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE / PREPARATION Name: Address: Foscavir (foscarnet sodium) Injection Clinigen Healthcare Limited Pitcairn House Crown Square First Avenue Burton-on-Trent
More informationNot available. S05999 (1 x 0.5mL vials), S06002 (10 x 0.5 vials) 63 Poplar Road, Parkville, Victoria 3052, Australia (24hr)
Pneumovax 23 SAFETY DATA SHEET Page 1 of 5 - IMPORTANT NOTICE This Safety Data Sheet (SDS) is prepared by Seqirus Pty. Ltd. in accordance with Safe Work Australia National Code of Practice for the Preparation
More information